Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma.
Since thallium-201 imaging has been reported as a potential means of follow-up of patients with differentiated thyroid carcinoma (DTC) during ongoing thyroid suppression therapy, the authors evaluated the diagnostic sensitivity of this procedure in 31 patients known to have metastases or local recurrence. Among 51 tumor sites 201TI imaging had a detection rate of 45% whereas 84% was noted for imaging with 131I administered in therapeutic doses. Thus, even though the effectiveness of the two radionuclides is not strictly comparable due to the difference in the administered doses, Thallium imaging cannot be recommended as the only modality for the follow-up of patients with DTC. Six of the eight tumor sites negative with 131I were positive with 201TI (especially metastatic cervico-mediastinal lymph nodes). So 201TI imaging may particularly be helpful in localizing metastases or recurrences in patients with a negative 131I scan and abnormal levels of serum thyroglobulin.
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D011446:Prospective Studies; D013794:Thallium Radioisotopes; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed; D014915:Whole-Body Counting
D007457:Iodine Radioisotopes; D013794:Thallium Radioisotopes